Birchview Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $358K | Hold |
40,000
| – | – | 0.36% | 48 |
|
|
2025
Q1 | $300K | Hold |
40,000
| – | – | 0.26% | 45 |
|
|
2024
Q4 | $301K | Hold |
40,000
| – | – | 0.24% | 47 |
|
|
2024
Q3 | $304K | Hold |
40,000
| – | – | 0.26% | 46 |
|
|
2024
Q2 | $247K | Buy |
40,000
+20,000
| +100% | +$124K | 0.23% | 47 |
|
|
2024
Q1 | $102K | Hold |
20,000
| – | – | 0.08% | 56 |
|
|
2023
Q4 | $120K | Hold |
20,000
| – | – | 0.09% | 54 |
|
|
2023
Q3 | $142K | Hold |
20,000
| – | – | 0.12% | 49 |
|
|
2023
Q2 | $141K | Hold |
20,000
| – | – | 0.11% | 50 |
|
|
2023
Q1 | $167K | Hold |
20,000
| – | – | 0.13% | 47 |
|
|
2022
Q4 | $230K | Hold |
20,000
| – | – | 0.16% | 47 |
|
|
2022
Q3 | $252K | Hold |
20,000
| – | – | 0.18% | 50 |
|
|
2022
Q2 | $212K | Hold |
20,000
| – | – | 0.15% | 50 |
|
|
2022
Q1 | $325K | Hold |
20,000
| – | – | 0.23% | 49 |
|
|
2021
Q4 | $277K | Hold |
20,000
| – | – | 0.18% | 56 |
|
|
2021
Q3 | $287K | Hold |
20,000
| – | – | 0.2% | 54 |
|
|
2021
Q2 | $316K | Hold |
20,000
| – | – | 0.19% | 54 |
|
|
2021
Q1 | $203K | Hold |
20,000
| – | – | 0.12% | 52 |
|
|
2020
Q4 | $149K | Hold |
20,000
| – | – | 0.09% | 47 |
|
|
2020
Q3 | $69K | Hold |
20,000
| – | – | 0.05% | 50 |
|
|
2020
Q2 | $95K | Hold |
20,000
| – | – | 0.06% | 51 |
|
|
2020
Q1 | $40K | Hold |
20,000
| – | – | 0.04% | 46 |
|
|
2019
Q4 | $69K | Hold |
20,000
| – | – | 0.05% | 52 |
|
|
2019
Q3 | $57K | Hold |
20,000
| – | – | 0.04% | 49 |
|
|
2019
Q2 | $76K | Buy |
+20,000
| New | +$76K | 0.05% | 50 |
|